


PANTERA

A BETTER FIGHT FOR LIFE



STATE OF THE ART ²²⁵Ac FACILITY

PanTera is dedicated to bringing new hope to cancer patients by enabling the widespread use of radiopharmaceuticals for precision treatment!

PanTera is building a dedicated Actinium-225 production facility (the APC) in Mol.
A state-of-the-art facility specifically for large-scale ²²⁵Ac supply.

The facility's design took 3 years to ensure safe, sustainable operation with minimal waste. The construction began in October 2025 after receiving all key environmental and nuclear permits!

Actinium-225 (²²⁵Ac) is a potent alpha-emitting radioisotope used in targeted alpha therapy (TAT) for cancer, highly energetic but with a very short path in tissue, enabling precise tumour cell kill while sparing nearby healthy cells.

Pantera will produce up to 100 Ci/year by 2029, which will help more than 100.000 patients in Europe and across the globe.

- 2022-2025: Design and permitting process
- 2025-2027: APC construction
- 2027-2028: Equipment installation and testing
- 2029: First commercial ²²⁵Ac supply from APC

More information 